Anti-HLA class I antibody binding to airway epithelial cells induces production of fibrogenic growth factors and apoptotic cell death: a possible mechanism for bronchiolitis obliterans syndrome

Jaramillo, Andrés; Smith, Craig R.; Maruyama, Takahiro; Zhang, Leiying; Patterson, G. Alexander; Mohanakumar, T.

doi:10.1016/s0198-8859(03)00038-7

Cited by 111 publications

(105 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…MAUCK et al [150] have shown in vivo that BEC can induce an allo-immune response and express various growth factors that play a role in the development of BO. These results were confirmed by JARAMILLO et al [151], showing that antibodies against human leukocyte antigen class I are able to activate BEC to secrete fibrotic factors.…”

Section: Emt and Bo Following Lung Transplantationsupporting

confidence: 63%

“…Other inflammatory cytokines such as IL-1b and IL-8 enhance the process of EMT [29]. HGF has also been found in the BAL of BO patients [151]. This growth factor plays a role in the repair of the epithelium following injury and can partially induce EMT [143,166].…”

Section: Emt and Bo Following Lung Transplantationmentioning

confidence: 99%

“…Some studies have described BEC as the major target of the immune response. These cells play a central role in the development of BO [150][151][152]. MAUCK et al [150] have shown in vivo that BEC can induce an allo-immune response and express various growth factors that play a role in the development of BO.…”

Section: Emt and Bo Following Lung Transplantationmentioning

confidence: 99%

See 2 more Smart Citations

Tissue remodelling in chronic bronchial diseases: from the epithelial to mesenchymal phenotype

Pain

Bermúdez

Lacoste

et al. 2014

European Respiratory Review

171

128

View full text Add to dashboard Cite

Airway remodelling is a critical feature of chronic bronchial diseases, characterised by aberrant repair of the epithelium and accumulation of fibroblasts, which contribute to extracellular matrix (ECM) deposition resulting in fixed bronchial obstruction. Recently, epithelial-mesenchymal transition (EMT) has been identified as a new source of fibroblasts that could contribute to the remodelling of the airways. This phenomenon consists of the loss of the epithelial phenotype by bronchial epithelial cells and the acquisition of a mesenchymal phenotype. These cells are then able to migrate and secrete ECM molecules. Herein, we review the different types of EMT. We will then focus on the signalling pathways that are involved, such as transforming growth factor-b and Wnt, as well as the more recently described Sonic Hedgehog pathway. Finally, we will highlight the implication of EMT in airway remodelling in specific chronic bronchial pathologies, such as asthma, chronic obstructive pulmonary disease and bronchiolitis obliterans following lung transplantation. Despite the limitations of in vitro models, future studies of EMT in vivo are warranted to shed new light on the pathomechanisms of bronchial obstruction. @ERSpublications Epithelial-mesenchymal transition in chronic bronchial remodelling diseases

show abstract

Section: Emt and Bo Following Lung Transplantationsupporting

confidence: 63%

Section: Emt and Bo Following Lung Transplantationmentioning

confidence: 99%

See 1 more Smart Citation

Tissue remodelling in chronic bronchial diseases: from the epithelial to mesenchymal phenotype

Pain

Bermúdez

Lacoste

et al. 2014

European Respiratory Review

171

128

View full text Add to dashboard Cite

show abstract

“…A number of studies have suggested possible mechanistic effects of HLA-specific antibodies in the development of obstructive airway disease. [37][38][39][40][41] The majority of these studies utilized W6/32, a monoclonal antibody directed against a monomorphic determinant on HLA Class I molecules. Ligation of W6/32 to epithelial cells has been shown to cause cell proliferation, production of growth factors and chemotactic factors, as well as cell death through apoptosis.…”

Section: Discussionmentioning

confidence: 99%

De novo donor HLA-specific antibodies predict development of bronchiolitis obliterans syndrome after lung transplantation

Safavi

Robinson

Soresi

et al. 2014

The Journal of Heart and Lung Transplantation

114

104

View full text Add to dashboard Cite

(2014) De novo donor HLA-specific antibodies predict development of bronchiolitis obliterans syndrome after lung transplantation. The Journal of Heart and Lung Transplantation, 33 (12). pp. 1273 -1281 . ISSN 1053 -2498 This version is available from Sussex Research Online: http://sro.sussex.ac.uk/56766/ This document is made available in accordance with publisher policies and may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version. Please see the URL above for details on accessing the published version. Copyright and reuse:Sussex Research Online is a digital repository of the research output of the University.Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable, the material made available in SRO has been checked for eligibility before being made available.Copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way. There was a significant reduction in patient survival associated with de novo DSA (HR ¼ 1.886, p ¼ 0.047). In multivariable analyses, de novo DSA was an independent predictor for development of all stages of BOS as well as an independent predictor of poor patient survival. CONCLUSIONS: De novo DSA is a major risk factor for progression to BOS and shorter patient survival. Treatments to remove antibodies or limit antibody-mediated damage could be considered when DSA are first detected. However, a randomized, controlled trial of treatment options would enable a clearer understanding of the benefits, if any, of antibody-removal therapies.

show abstract

“…Acute cellular rejection is a risk factor for BOS and recent data also suggest that acute or chronic antibody-mediated rejection may play a role in the development of BOS [107]. Anti-HLA class I antibody binding to epithelial or endothelial cells induce cell proliferation and production of fibrogenic growth factors [108]. Graft damage related to rejection may expose cryptic antigens (e.g.…”

Section: Bronchiolitis Obliterans After Lung Transplantationmentioning

confidence: 99%

Small airways diseases, excluding asthma and COPD: an overview

Burgel¹,

Bergeron²,

Blic³

et al. 2013

European Respiratory Review

104

View full text Add to dashboard Cite

This review is the summary of a workshop on small airways disease, which took place in Porquerolles, France in November 2011. The purpose of this workshop was to review the evidence on small airways (bronchiolar) involvement under various pathophysiological circumstances, excluding asthma and chronic obstructive pulmonary disease. Histopathological patterns associated with small airways disease were reviewed, including cellular and obliterative bronchiolitis. Many pathophysiological conditions have been associated with small airways disease including airway infections, connective tissue diseases and inflammatory bowel diseases, bone marrow and lung transplantation, common variable immunodeficiency disorders, diffuse panbronchiolitis, and diseases related to environmental exposures to pollutants, allergens and drugs. Pathogenesis, clinical presentation, a computed tomography scan and pulmonary function test findings are reviewed, and therapeutic options are described with the objective of providing an integrative approach to these disorders.

show abstract

Anti-HLA class I antibody binding to airway epithelial cells induces production of fibrogenic growth factors and apoptotic cell death: a possible mechanism for bronchiolitis obliterans syndrome

Cited by 111 publications

References 41 publications

Tissue remodelling in chronic bronchial diseases: from the epithelial to mesenchymal phenotype

Tissue remodelling in chronic bronchial diseases: from the epithelial to mesenchymal phenotype

De novo donor HLA-specific antibodies predict development of bronchiolitis obliterans syndrome after lung transplantation

Small airways diseases, excluding asthma and COPD: an overview

Contact Info

Product

Resources

About